Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Botulinum toxin in the management of dystonia

  • 63 Accesses

  • 2 Citations

This is a preview of subscription content, log in to check access.

References and Recommended Reading

  1. 1.

    Lesser RP, Fahn S:Dystonia: a disorder often misdiagnosed as a conversion reaction.Am J Psychiatry 1978, 135:349–352.

  2. 2.

    Ozelius LJ, Hewett JW, Page CE, et al.:The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.Nat Genet 1997, 17:40–48.

  3. 3.

    Greene P, Shale H, Fahn S:Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.Mov Disord 1988, 3:46–60.

  4. 4.

    Jankovic J, Brin MF:Therapeutic uses of botulinum toxin.N Engl J Med 1991, 324:1186–1194.

  5. 5.

    Lew MF, Adornato BT, Duane DD, et al.:Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.Neurology 1997, 49:701–707.

  6. 6.

    Jankovic J, Orman J:Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.Neurology 1987, 37:616–623.

  7. 7.

    Brans JW, Lindeboom R, Snoek JW, et al.:Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.Neurology 1996, 46:1066–1072.

  8. 8.

    Of major importance Comella CL, Jankovic J, Shannon KM, et al.:Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 2005, 65:1423–1429. Forst tandomized, blinded, head-to-head comparative study between toxin serotypes.

  9. 9.

    Of importance Pappert EJ, Leong MS, Royal MA:Botulinum toxin type B compared with type A in the treatment of toxin-naive patients with cervical dystonia: results from a randomized, double-blind study.Neurology 2006, 66(Suppl 2):252. Randomized, blinded, head-to-head comparison of botulinum toxins type A and B, currently vailable in abstract form.

  10. 10.

    Comella CL, Buchman AS, Tanner CM, et al.:Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.Neurology 1992, 42:878–882.

  11. 11.

    Barbano RL:Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful.Muscle Nerve 2001, 24:1567–1568.

  12. 12.

    Jankovic J:Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required.Muscle Nerve 2001, 24:1568–1570.

  13. 13.

    Borodic GE, Pearce LB, Smith K, et al.:Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle.Head Neck 1992, 14:33–37.

  14. 14.

    Jankovic J, Schwartz K:Botulinum toxin injections for cervical dystonia.Neurology 1990, 40:277–280.

  15. 15.

    Berman B, Seeberger L, Kumar R:Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.Mov Disord 2005, 20:233–237.

  16. 16.

    Haussermann P, Marczoch S, Klinger C, et al.:Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.Mov Disord 2004, 19:303–308.

  17. 17.

    Jankovic J, Hunter C, Dolimbek BZ, et al.:Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.Neurology 2006, 67:2233–2235.

  18. 18.

    Jankovic J, Vuong KD, Ahsan J:Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology 2003, 60:1186–1188.

  19. 19.

    Brin MF, Lew MF, Adler CH, et al.Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 1999, 53:1431–1438.

  20. 20.

    Factor SA, Molho ES, Evans S, Feustel PJ:Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.Mov Disord 2005, 20:1152–1160.

  21. 21.

    Blackie JD, Lees AJ:Botulinum toxin treatment in spasmodic torticollis.J Neurol Neurosurg Psychiatry 1990, 53:640–643.

  22. 22.

    Truong D, Duane DD, Jankovic J, et al.:Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebocontrolled study.Mov Disord 2005, 20:783–791.

  23. 23.

    Ranoux D, Gury C, Fondarai J, et al.:Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.J Neurol Neurosurg Psychiatry 2002, 72:459–462.

  24. 24.

    Ben Simon GJ, McCann JD:Benign essential blepharospasm.Int Ophthalmol Clin 2005, 45:49–75.

  25. 25.

    Kerty E, Eidal K:Apraxia of eyelid opening: clinical features and therapy.Eur J Ophthalmol 2006, 16:204–208.

  26. 26.

    Pang AL, O’Day J:Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?Clin Experiment Ophthalmol 2006, 34:441–444.

  27. 27.

    Silveira-Moriyama L, Goncalves LR, Chien HF, et al.:Botulinum toxin A in the treatment of blepharospasm: a 10-year experience.Arq Neuropsiquiatr 2005, 63:221–224.

  28. 28.

    Truong DD, Jost WH:Botulinum toxin: clinical use.Parkinsonism Relat Disord 2006, 12:331–355.

  29. 29.

    Bhidayasiri R, Cardoso F, Truong DD:Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.Eur J Neurol 2006, 13:21–29.

  30. 30.

    Tan EK, Jankovic J:Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.Neurology 1999, 53:2102–2107.

  31. 31.

    Bhattacharyya N, Tarsy D:Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.Arch Otolaryngol Head Neck Surg 2001, 127:389–392.

  32. 32.

    Adler CH, Factor SA, Brin M, et al.:Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.Mov Disord 2002, 17:158–161.

  33. 33.

    Blitzer A, Sulica L:Botulinum toxin: basic science and clinical uses in otolaryngology.Laryngoscope 2001, 111:218–226.

  34. 34.

    Truong DD, Bhidayasiri R:Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.Eur J Neurol 2006, 13:36–41.

  35. 35.

    Blitzer A, Brin MF, Stewart CF:Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.Laryngoscope 1998, 108:1435–1441.

  36. 36.

    Smith ME, Ford CN:Resistance to botulinum toxin injections for spasmodic dysphonia.Arch Otolaryngol Head Neck Surg 2000, 126:533–535.

  37. 37.

    Pullman SL, Greene P, Fahn S, et al.:Approach to the treatment of limb disorders with botulinum toxin A.Arch Neurol 1996, 53:617–624.

  38. 38.

    Gordon NS:Focal dystonia, with special reference to writer’s cramp.Int J Clin Pract 2005, 59:1088–1090.

  39. 39.

    Das CP, Dressler D, Hallett M:Botulinum toxin therapy of writer’s cramp.Eur J Neurol 2006, 13:55–59.

  40. 40.

    Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al.:Botulinum toxin for writer’s cramp: a randomised, placebocontrolled trial and one year follow up.J Neurol Neurosurg Psychiatry 2007, 78:264–270.

  41. 41.

    Hsiung GY, Das SK, Ranawaya R, et al.:Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.Mov Disord 2002, 17:1288–1293.

Download references

Author information

Correspondence to Eric S. Molho MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cardona-Garcia, O.D., Higgins, D.S. & Molho, E.S. Botulinum toxin in the management of dystonia. Curr Treat Options Neurol 9, 224 (2007). https://doi.org/10.1007/BF02938412

Download citation


  • Dystonia
  • Botulinum Toxin
  • Cervical Dystonia
  • Botulinum Toxin Injection
  • Botulinum Toxin Type